infliximab-dyyb Inflectra
Selected indexed studies
- Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). (Gastroenterology, 2024) [PMID:38788861]
- Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. (BioDrugs, 2016) [PMID:27650650]
- Inflectra - an infliximab biosimilar. (Med Lett Drugs Ther, 2017) [PMID:28118651]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Clinical Pharmacokinetics and Pharmacodynamics of Infliximab in the Treatment of Inflammatory Bowel Disease. (2018) pubmed
- Subcutaneous Infliximab (CT-P13 SC) as Maintenance Therapy for Inflammatory Bowel Disease: Two Randomized Phase 3 Trials (LIBERTY). (2024) pubmed
- Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases. (2016) pubmed
- Inflectra - an infliximab biosimilar. (2017) pubmed
- Efficacy of Biosimilar Infliximab-Dyyb in Non-Infectious Uveitis. (2024) pubmed
- Impact of Infliximab-dyyb (Infliximab Biosimilar) on Clinical and Patient-Reported Outcomes: 1-Year Follow-up Results from an Observational Real-World Study Among Patients with Inflammatory Bowel Disease in the US and Canada (the ONWARD Study). (2022) pubmed
- Efficacy and safety of infliximab biosimilar Inflectra(®) in severe sarcoidosis. (2018) pubmed
- Process and Clinical Outcomes of a Biosimilar Adoption Program with Infliximab-Dyyb. (2020) pubmed
- Effectiveness of Switching from Reference Product Infliximab to Infliximab-Dyyb in Patients with Inflammatory Bowel Disease in an Integrated Healthcare System in the United States: A Retrospective, Propensity Score-Matched, Non-Inferiority Cohort Study. (2020) pubmed
- Real-world experience with biosimilar infliximab-adba and infliximab-dyyb among infliximab-naïve patients with inflammatory bowel disease in the Veterans Health Administration. (2024) pubmed